SCHEMBL6326378

SCHEMBL6326378

CC(CO)NS(=O)(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAMTS4 O75173 6/20 0.65
MMP2 P08253 9/20 0.61
MMP9 P14780 7/20 0.61
MMP13 P45452 3/20 0.61
MMP3 P08254 2/20 0.61
MMP1 P03956 1/20 0.61
MMP7 P09237 1/20 0.61
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA9 Q16790 1/20 0.56
CA14 Q9ULX7 1/20 0.56
NR3C1 P04150 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MMP8 P22894 1/20 0.55
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
SLC1A3 P43003 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326385 1.00 ADAMTS4 (0.65) ADAMTS4MMP2MMP9MMP13MMP3
SCHEMBL31310984 0.90 SMN1; SMN2 (0.67) ADAMTS4MMP2MMP9MMP13MMP3
SCHEMBL31310982 0.90 SMN1; SMN2 (0.67) ADAMTS4MMP2MMP9MMP13MMP3
SCHEMBL20021999 0.85 MMP2 (0.63) ADAMTS4MMP2MMP9MMP13MMP3
SCHEMBL18649869 0.83 MMP2 (0.67) ADAMTS4MMP2MMP9MMP13MMP3
SCHEMBL16519485 0.81 CA2 (0.68) MMP2MMP9MMP13MMP3MMP1
SCHEMBL4752500 0.81 CA2 (0.68) MMP2MMP9MMP13MMP3MMP1
SCHEMBL6324016 0.81 ADAMTS4 (0.53) ADAMTS4CA12CA1CA2CA9
SCHEMBL16519484 0.81 CA2 (0.68) MMP2MMP9MMP13MMP3MMP1
SCHEMBL6324018 0.81 ADAMTS4 (0.53) ADAMTS4CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 ADAMTS4 33/4885MMP2 26/4885MMP9 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.